Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial.
Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial.
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More